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Interleukin-6 in relation to other proinflammatory 
cytokines5 chemotactic activity and neutrophil 
activation in rheumatoid synovial fluid
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M artin  H  van Rijswijk
Abstract
Objective—To evaluate the relation 
between synovial fluid (SF) concentra­
tions of interleukin-6 (IL-6) and other 
mediators of inflammation which are re­
sponsible for joint degradation in rheuma­
toid arthritis (RA).
Methods—We measured IL-6, IL-1 (i, 
tumour necrosis factor ol (TNFa), gran­
ulocyte macrophage colony stimulating 
factor, IL-8, and polymorphonuclear 
leucocyte (PMNL) chemotaxis and de­
granulation in SF from patients with RA 
(n = 30) in the early phase of the disease* 
Results—In a cross-sectional study IL-6 
concentrations correlated with those of 
IL-lp, IL-8 and with PMNL activation 
as reflected by lactoferrin concen­
trations. In a longitudinal study, changes 
in IL-6 concentrations correlated with 
changes in TNF«, IL-8 and lactoferrin 
concentrations.
Conclusion—IL-6 in SF appears to reflect 
the local proinflammatory, potentially 
erosive activity in RA. This supports the 
use of acute phase proteins, which are 
mainly induced by IL-6, as variables to 
monitor the course of RA.
(Ann Rheum Dis 1 095; 54: 33- 38)
Rheumatoid arthritis (RA) is a 
inflammatory disease localised preferentially in 
the synovial joints. Chronic synovitis often 
leads to irreversible destruction of cartilage and 
periarticular bone. T he inflamed synovium is 
characterised by infiltration of macrophages, 
T  and B cells, and local proliferation of 
synoviocytes. T h e  highly active macrophages 
and synoviocytes have been shown to be strong 
producers of cytokines, in particular the 
proinflammatory cytokines such as inter­
leukin** 1 (IL -l) , tum our necrosis factor « 
(T N Fa), in ter leu kin-8  (IL-8), granulocyte 
macrophage colony stimulating factor (GM - 
GSF) and interleukin-6 (IL-6 ) .1 * 
Proinflammatory cytokines are thought to 
play a major role in chronic inflammation and 
joint de s t ru c t i o n i n R A. IL-1 and T  N Fot 
stimulate the proliferation of synoviocytes and 
the secretion of prostaglandins, collagenase, 
stromelysin, neutrophil proteases., and oxygen 
radicals, thus having potent catabolic actions 
on cartilage and bone . 1 Both also induce the
synthesis and secretion of other cytokines in 
the synovium, in particular IL -6  and IL -8 .1 2 1 
T he activities of IL -8  include chemotactic 
attraction and activation of polymorpho­
nuclear leucocytes (PM N L ) ; 1 h These PM N L, 
which may be present in large numbers in the 
synovial fluid, are thought to contribute to 
destruction of cartilage through the release of 
degradative enzymes .7
The local tissue damaging potential of IL -6 
is not clear; it docs not, for example, stimulate 
the production of prostaglandin E> or 
proteinases by hum an synovial cells, and has 
no chemotactic properties. However, IL -6  is 
the major inducer of the systemic acute phase 
response, in particular of hepatic acute phase 
proteins ,9 T he  acute phase response, as 
measured by the erythrocyte sedimentation 
rate (BSR) or C reactive protein (CRP) 
concentrations, is commonly used in clinical 
practice to monitor disease activity. In previous 
studies a correlation between the course of 
clinical disease activity (as measured by joint 
swelling), serum concentrations of CRP, 
and progression of radiological joint damage 
has been demonstrated.tJ 11 Moreover, IL -6 
concentrations in synovial fluid have been 
shown to be related to local disease activity in 
rheumatoid arthritis .1 T he  aim of the present 
study was to evaluate to what extent 
concentrations of IL -6 in the synovial fluids of 
patients with early RA may be considered to be 
representative of those of the group of factors 




One hundred consecutive patients attending 
the Department of Rheumatology, Groningen, 
who had rheumatoid arthritis (American 
Rheumatism Association (ARA) criteria) of 
disease duration less than one year, were 
invited to participate in a prospective follow up 
study. Disease onset was deli tied as the date on 
which the patient first presented complaining 
of the disease. Synovial fluid (SF) was obtained 
from 30 of these patients in an early phase of 
the disease during therapeutic arthrocentesis 
of actively inflamed painful swollen joints. In 
all cases corticosteroid (triamcinolone) was 
administered into the joint after aspiration of 
the SF. Fourteen patients had more than one 
aspiration early in the course of the disease,
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and 61 different samples (knee 54, shoulder 7) 
were available for analysis. M ean duration of 
the disease until the first aspiration was 21 
months (range 3-50, median 17) and the mean 
time between two aspirations was seven 
months (range 1-25, median 7). All patients 
but one were rheumatoid factor positive. At the 
time of the aspiration, all patients were treated 
with non-steroidal anti-inflammatory drugs 
(NSAIDs) and 23 received disease modifying 
anti-rheumatic drugs (DMARDs) in addition 
(hydroxychloroquine n = 10 , i.m. gold n = 9, 
d-penicillamine n = 4). F ou r patients were 
treated with low dose prednisolone,
SF samples were collected into sterile tubes 
with EDTA and immediately placed on 
melting ice. Cells were removed by centrifuga­
tion and SF were stored at -20°C  until use. 
Before assay each SF was treated with hyaluro- 
nidase (Sigma, type I-S, St Louis, M O ) at a 
concentration of 10 U/ml for one hour at 37°C 
and then centrifuged at high speed to remove 
particles. Hyaluronidase treatm ent was per­
formed to decrease the viscosity of the SF and 
to prevent the possible interference in the 
immunoassays of the combined presence of 
rheumatoid factor and hyaluronic acid ,13
C Y TO K IN E ASSAYS
IL -6  was determined by bio ass ay with the IL- 
6-dependent mouse hybridoma cell line B9.H 
Heat inactivated synovial fluid samples were 
serially diluted in medium consisting of RPMI- 
1640 (Gibco BRL, Gaithersburg, MD) 
supplemented with 13% fetal calf serum, 
60 |xg/ml3 gentamycin, 2 m mol/1 glutamin,
1 mmol/1 sodium pyruvate and 50 fjumol/l 
[3-mercaptoethanol; 60 jxl test samples were 
added to 96 well culture plates (Costar, 
Cambridge, MA). Five thousand cells per well 
were added to a final volume of 100 jjJ and 
cultured for 72 hours. Cell proliferation was 
measured in a colorimetric assay with M T T - 
tetrazolium (Sigma) as described by 
Mosman,^ As standard we used recombinant 
human IL-6  (107 U/mg) from Genzyme 
(Boston, MA).
In addition, concentrations of IL -6  were 
determined with two different immunoassays. 
The first was an ELISA as described by Helle 
et a lu' using a combination of the monoclonal 
antibody, mAb IL-6-16* and the polyclonal 
antibody, Sh-a-IL-6 , The sheep anti-IL -6  was 
biotinylated using LC-biotin-N~hydroxysucci- 
mide ester (Pierce, Rockford, IL) accord­
ing to the manufacturer's instructions. SF 
were measured in four serial dilutions 
(40-160-640-25 60 X) in the presence of an 
excess of normal sheep serum and after incuba­
tion the microplates were washed with phos­
phate buffered saline with 0*05% Tween -20 
before incubation with streptavidine-horse- 
radish peroxidase (IiRPO) (Dakopatts A/S, 
Denmark) at 5000-fold dilution. Signal ampli­
fication was then performed by catalysed 
reporter deposition using 15 minutes of 
incubation with biotin-tyramine (BT) pre­
pared as described by Bobrow according to 
method A ,17 A second incubation with strepta-
vidine-HRPO ( 1 0 0 0 X dilution) for 15 minutes 
was performed. Ortho-phenyl diamine was 
added and after 20  minutes the reaction was 
terminated with 1 mol/1 H 2SO.}. The absorb­
ance was read at 492 nm on a Titertek 
Multiscan. As standard we used recombinant 
human IL -6  (Genzyme) with a detection range
of 0 -S- 100  pg/ml.
The second immunoassay for IL-6 in SF was 
an IL -6  enzyme amplified sensitivity immuno 
assay (EASIA) (kit by Medgenix Diagnostics, 
Fleurus Belgium). Monoclonal antibodies 
directed against distinct epitopes of IL-6  were 
used; samples were diluted 50-fold, standards 
were in the range 20-2000 pg/ml, The colour 
reaction was performed with tetramethyl- 
benzydine and hydrogen peroxide and absorb­
ance was read at 450 nm  and 490 nm on a 
Vmax EASIA reader. Data were calculated 
using a polychromatic data reduction method 
(kindly provided by Medgenix).
For measurement of IL-1 (3, T N F a  and 
G M -C SF in SF we used EASIAs (Medgenix) 
in which samples were tested undiluted, 
monoclonal antibodies were used and reading 
was according to the method used in the IL -6 
EASIA. IL-1 ¡3 and G M -C SF standards were in 
the range 25-2000 pg/ml, T N F a  standards in 
the range 15-1500 pg/ml. Soluble T N F  
receptors do not interfere with the detection of 
T N F a  in this EASIA, in which the same 
reagents are used as in the TNF-immunoradio- 
metric assay (Medgenix) . 18
IL-1 ¡3 in SF was also tested in a high 
sensitivity IL-1 (3 ELISA kit (Cistron Bio­
technology, Pinehrook, NJ). A monoclonal 
antibody was used as coating antibody and a 
polyclonal rabbit anti-IL-lp  as detecting 
antibody. Samples were diluted fivefold and 
standards were in the range 5-150 pg/ml; the 
lower limit of detection was 5 pg/ml,
IL-8  in SF was determined using a hum an 
IL -8  immunoassay (Quantikine, R & D 
Systems, Abingdon, UK). A monoclonal anti­
body to IL -8  was coated to the microtitreplate; 
the second antibody consisted of an H R PO - 
labelled polyclonal antibody. The standard 
consisted of recombinant human IL-8 used in 
concentrations of 25-3000 pg/ml; samples 
were diluted 10-fold.
CHK M O TA X IS A S S A Y
Normal hum an P M N L  were isolated from  
freshly drawn venous blood anticoagulated 
with EDTA, from the same donor for each 
assay. After density gradient centrifugation on 
Lymphoprep (Nycorned Pharma A/S, Oslo, 
Norway) neutrophils were separated from  
erythrocytes by lysis for 10 minutes with cold 
ammonium chloride (155 mmol/1 N H 4C1, 0*1 
mmol/1 EDTA). Cells were washed twice with 
0-9% saline, once with Hanks's balanced salt 
solution (HBSS) (Gibco) and suspended in 
HBSS with 0 -5% bovine serum albumin 
(HBSA) at 2*5 10() cells/ml. Cell viability was 
tested by Trypan Blue exclusion and was 
>97%.
Chemotaxis was measured according to 
Boyden, 19 using blind well chambers (N euro­
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probe, Cabin John, MD) with a volume o f  
200  jxl attractant or control medium in the 
bottom and 200  fxl cell suspension in the top 
compartment. The chambers were separated 
by a 13 mm diameter 3 juim pore size 
polycarbonate filter (polyvinyl pyrrolidone 
free, Nuclepore Corporation, Pleasanton, 
CA). Before assay, filters were soaked in 
0*5 mol/1 acetic acid for two minutes and then 
washed with HBSA .20 SF were measured at 
five twofold dilutions starting at 1:10 ; as 
control medium we used FIBSA. Chambers 
were incubated for 4-5 minutes at 37°C in 
humidified 95% air/5% carbon dioxide. After 
incubation the cells in the upper chamber were 
counted using a coulter counter. Chemotactic 
index (CTI) was expressed as the percentage 
of cells migrating towards the chemoattractant 
and was calculated as:
C T I = 100 X [1 -  (cells in sample well/cells
in control well)]
Recombinant human IL -8  (Genzyme) was 
used as standard in the chemotaxis assay at 
concentrations of 0*5-50 ng/ml, resulting in a 
linear dose-response relationship between the 
log of the IL -8  concentration and the C T I from
1 to 20 ng/ml of IL-8 . In addition to 
the SF samples, different combinations o f  
recombinant human IL-8 0*3-30 ng/ml with 
T N F a  0*01-10 ng/ml or IL -1 0*01-10 ng/ml 
or with both, were tested in the assay to 
evaluate possible synergism of the cytokines. 
Contribution of IL -8 to the chemotactic 
activity of SF was tested by performing the 
chemotaxis assay in the presence of an excess 
of neutralising monoclonal antibody to IL -8  
(4 (Jig/ml) (clone 6217.11, R & D  Systems), 
Percentage inhibition was expressed as:
100 X [1 -  (CTI + anti IL-8/C T I - a n t i  IL -8)]
L A C T O F E R R IN  AND IG M -R H E  U M  A T O ID  F A C T O R  
ELISA
Lactoferrin concentrations were measured by 
ELISA as follows: microtitre plates were 
coated with F(abs)2-rabbit-anti-human-lacto- 
ferrin (Jackson Immunoresearch, Westbroke, 
PA). SF were tested in four dilutions 
(200-800-3200-12 800X) and the conjugate 
was HRPO-rabbit-anti-human-lactoferrin (Jack­
son Immunoresearch). The standard consisted 
of a supernatant from activated P M N L  and 
was in the range 0 *8 -1 0 0  ng/ml lactoferrin. 
IgM rheumatoid factor (IgM-RF), which did no t 
cross react in that ELISA was itself measured by 
ELISA as described before,21 on microtitre 
plates coated with aggregated human IgG and 
expressed as IU/ml, using a standard calibrated 
against the WHO standard.
STA TISTIC S
Correlations between the results of the IL -6  
assays were calculated using the Pearson 
test and correlations between the other 
biochemical parameters were calculated by 
Spearman test or multiple linear regression 
analysis. To compare a biochemical variable in 
two groups we used a two-tailed t test.
Results
1 1 f t  M E A SU R E M E N T S
IL-6  concentrations in all 61 SF samples were 
measured with three assays. Hyaluronidase 
treatment had no influence on results of IL -6 
measurements. Possible interference by IgM- 
RF was unlikely because samples were 
measured in the presence of an excess of 
normal sheep serum; furthermore, there was 
no correlation between the SF concentrations 
of IL -6  and those of IgM-RF (present in 
concentrations of 5-850 (mean 153, median 
65) IU/ml (data not shown)). The Pearson 
correlation coefficient between bioassay results 
and the EASIA was 0*915, between bioassay 
and the IL -6  ELISA was 0*809, and between 
EASIA and ELISA was 0-890 (all highly 
s ignifi ca n t : n = 61, p < 0 * 0 0 1 ). For fur the r 
calculations we used the IL-6 values of the 
bioassay and the ELISA.
IL~.ip, G M -C S F ,  T N F u  A N D  IL-8 ASSAYS
Table 1 shows the results of the cytokine 
measurements in the first SF  sample of each 
patient (n = 30), including IL-6 . Concentra­
tions of IL-1 (3 and G M -C SF were below the 
detection limit in all EASIA samples, but 
IL-1|3 was detectable in all ELISA samples. 
Positive results for T N F a  and IL-8  were 
obtained in all samples. There was no influence 
of hyaluronidase treatment on the results of 
these IL - lp ,  T N F a  and IL-8  measurements.
C ME M O' l’AXIS AS S A Y
This assay appeared to be sensitive, as 10 ng/ml 
IL -8 gave a mean C T I of 51-8 (SD 5*8)% in 
six different experiments with P M N L  from the 
same donor. Mean C T I in the SF samples, 
tested in a dilution of 1:20, was 32*5% 
(2-62%, median 30%). In this 1:20 dilution., 
all SF samples yielded results within the linear 
range of the assay. Addition of T N F a  or IL-1, 
or both, to a range of concentrations of IL-8  
corresponding to those found in SF samples, 
did not increase the chemotactic response in 
this assay compared with IL -8  alone (data not 
shown). Chemotaxis induced by an excess of 
recombinant hum an IL -8  (50-200 ng/ml), 
leading to a plateau of chemotaxis (C TI 60%), 
was totally inhibited by addition of 4 |xg/ml and 
IL-8 ; that of SF  (measured at 1:20  dilution) 
was inhibited by 22 (28)% (range <5-77% ) in 
eight SF samples in either the presence or the 
absence of 4 (xg/ml anti IL-8 .
IN T E R R E L A T IO N  B E T W E E N  IL~fi A N D  O T H E R  
C Y T O K IN E S , L A C T O F E R R IN  A N D  C H E M O T A X IS  
IN SF
Table 2 shows the Spearman correlation matrix 
for the results of IL-6 , IL -1 (3, T N F a ,  IL-8 , 
lactoferrin, and chemotactic index, as 
measured in the first sample of each patient 
(n = 30). IL -6  correlated significantly with 
IL -1 (3 (p <  0*01) and IL -8  (p < 0*02), bu t not 
with T N F a  (p > 0 T). In addition, a significant 
correlation (p <  0 *0 0 1 ) was found between 
concentrations of IL -6  and those of lactoferrin
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(present in concentrations of 1*3-67 (mean 
14-3, median 9) (xg/ml). A similar significance 
was found for the correlation between IL -8  and 
lactoferrin concentrations, but correlations 
between C T I and individual cytokines or 
lactoferrin were not significant. Adding in the 
different cytokines as variables in a multiple 
regression analysis, no improvement in the 
prediction of the C T I was observed.
In 12 patients more than one aspiration of 
the same knee was necessary because of a flare 
of the arthritis in tha t joint. Patients with 
recurrent joint effusions appeared to have 
significantly greater concentrations of IL -6, 
IL~8 > and lactoferrin (first SF  sample from 
each patient) than patients with incidental knee 
swelling. T he  differences between the two 
groups could n o t  be related to differences in 
treatment with D M A R D s or prednisolone, 
which was similar for both groups,
In patients with recurrent swelling of the 
same joint, we analysed whether changes in 
IL-6  concentrations in the successive SF 
samples were related to changes in concen­
trations o f other cytokines and lactoferrin by 
expressing the cytokine and lactoferrin values 
in the second and occasional th ird  aspirate as 
percentages of the values in the first SF for each 
patient. In  the  sequential samples bo th  higher 
and lower values were found compared with 
those in the first sample from an individual 
patient. T h e  Spearman correlations between 
the relative changes in concentrations of IL -6 
and IL -8, IL -6  and T N F a ,  IL -6  and lacto­
ferrin, and IL -8  and lactoferrin were significant 
(n = 19, p < 0 * 0 5 ) ,  whereas the coiTelation 
between the relative changes in concentrations 
of IL -6  and IL -1B were not (n  = 19, p>0*2) 
(table 3),
Tabic /  Conce» eraíúnzs of IL -6  (B L ISA ), IL - lß ,
TMFcXy and IL -8  in synovial fluids of 30 patients zoith R A  
(first sample o f each patient)
Median Runge Interquartile range
IL-6 (ng/1) 26 500 300-90 000 12 000-44 000
IL-lß (ng/1) 45*5 5-246 24-5-63*0
TNFafngfl) 58*5 10-295 35-0-02-0
IL-8 (ng/1) 1700 200-37 300 580-3270
Tabic 2 Correlations between cytokine concentrations^ lactoferrin concentrations and 
chemotactic index in synovial fh/icis of 3 0 patients with rheumatoid arthritis
IL-61: 11.-613 IL-Iß TNFa 1L-8 LF
IL -lß























IL-(iE: ELISA; IL-6B: bioassay; IL - lß ;  E L I SA-Cist ron. L F  = lacioferrin; CTI == chemotactic 
index. **p < Q'01 * ***p < 0*001.
Table 3 Correlations between relative changes (%) in 
cytokine and lactoferrin concentrations in sequential samples 
o f synovial flu id  (n ~ 19) from patients zoith recurrent 
sivelling o f the same joint
•I





IL-8 0*526* 0-242 0*267 -----------------------
LF 0*545* 0-681** 0*371 0^716**
IL-6E; ELISA; IL-lß: ELI SA- Gì stro n. LF = lactoferrin. 
*p < 0*05; **p<0-01.
Discussion
We examined the relationship between IL-6 
and other proinflammatory cytokines, and 
neutrophil chemo taxis and activation in 
synovial fluids of rheumatoid arthritis patients, 
in order to analyse to what extent IL-6 
concentrations in SF  reflect those o f other 
factors believed to be the main causes of bone 
and cartilage destruction in inflammatory 
arthritis.
We have confirmed previous reports22"25 of 
high concentrations of IL -6  in SF of patients 
with RA. Our study comprised only patients 
with early RA, but no comparison o f data 
related to disease duration could be made 
because most published studies did not 
mention the stage of the disease. Because 
previous studies used different methods or 
expressed results in arbitrary units an d  did 
not afford appropriate comparisons, we have 
compared three assays—a bioassay3 a 
commercially available ELISA and one which 
is not commercially available—and have 
expressed our results in ng/ml, calibrated 
against a recombinant hu-IL-6  standard. 
Despite the use of different antibodies, no 
differences were found between the results of 
the two immunoassays. In addition* IL -6 
concentrations as measured with the 
immunoassays and the bioassay were similar, at 
both high and low ranges of detection ,24 
indicating that IL -6  detected with these 
assays was both specific and biologically 
active.
Several investigators have tested SF for the 
presence of IL - ip  and have obtained 
conflicting results, depending on the m ethod  
used. Most bioassays could not demonstrate 
IL-1, which was attributed, in part, to the 
presence of inhibitors such as IL-1 receptor 
antagonist.24 26 Our inability to demonstrate 
the presence of IL-1 (3 with the EA SIA  
(Medgenix) was in sharp contrast with the 
results obtained with the ELISA (Cistron), 
This contradiction appears not to be merely a 
consequence of differences in sensitivity of 
these assays: in about 50% of the samples the  
concentrations measured with the E L IS A  
(Cistron) were >50 pg/ml and thus above the 
detection limit of the EASIA (Medgenix). 
Differences in reagents or in sensitivity to 
cross reacting substances in SF may have 
contributed to differences between resu lts  
from the two respective assays. Our E L IS A  
(Cistron) results agree with those from o th e r  
studies which used reagents from the sam e  
manufacturer.24 26“2a
Using an immunoassay having a sensitivity 
as low as 15 pg/ml and no known interference 
by soluble receptors,1B we detected T N F a  in  all 
our SF samples. Taking into account th e  
differences in detection limits of the assays 
used in other studies, our results are in  
agreement with those reported previously.29~M
Although the local production of G M -C S F  
in rheumatoid synovitis has been dem onstrated 
by several investigators,5 32 very few d a ta  
concerning G M -C SF concentrations in S F  
have been published. Xu et al5 dem onstrated  
GM-CSF-like activity in RA SF, but could n o t
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detect immun ore active G M -C SF in S F  using 
a radioimmunoassay with a sensitivity of 100 
pg/ml. This in contrast with their results from 
synovial tissue culture supernatants, in which 
G M -C SF could be identified both with the 
radioimmunoassay and with a bioassay. 
Despite using a more sensitive immunoassay 
(detection limit 25 pg/ml), we were not able to 
detect G M -CSF in any of die RA SF samples 
(n = 61). Using the same assay, we had been 
able to demonstrate G M -C SF in con­
centrations of 25-200 pg/ml in serum samples 
of an RA patient with Felty syndrome treated 
with recombinant human G M -C S F ,v' and in 
supernatants of IL-1 stimulated fibroblast and 
RA synoviocyte cultures (data not shown).
IL -8  has been shown to be a potent chemo- 
tactic factor for P M N L ,'1 In  our sensitive 
chemotaxis assay ( C T I ^ 2%), the m inim um  
concentration of recombinant-human-IL -8  for 
detection of chemotaxis was 0-4 ng/ml, 
resulting in a lower detection limit in SF 
(dilution 1:10) of 4 ng/ml. In  our study the 
concentrations of IL -8 in SF were in the range 
0 ’2-36 (median L0) ng/ml. We found a weak 
correlation between IL -8 concentration and 
chemotactic index, as described in other 
studies .34 This may be because the concen- 
trations of immun ore active IL -8  were greater 
than 4 ng/ml in only five of our SF samples; 
the amount of IL -8  in RA SF is probably not 
sufficient to account for the results of in vitro 
chemotaxis. In addition, we found no evidence 
of a possible synergism (in vitro) between IL -8  
and the other cytokines in the chemotaxis 
assay. It would appear that IL -8 in SF  is not 
the only chemotactic factor responsible for the 
accumulation of PM N L in RA SF .34 This was 
supported by the results of control experiments 
in the presence of an excess of a neutralising 
monoclonal antibody to hum an IL -8 . This 
concentration of antibody completely inhibited 
the chemotaxis induced by 200  ng/ml re­
combinant human IL-8 , whereas the SF- 
induced chemotaxis was only inhibited by 22 
(28)%. This is in agreement with the results of 
Koch ,4 who found that chemotactic activity 
was only partly inhibited after preincubation
with anti-IL-8 .
P M N L  are a major source of enzymes, 
including those which are able to degrade 
cartilage. Lactoferrin is a PMNL-specific 
protein, which is released from the specific 
granules upon activation. T he am ount of 
lactoferrin in SF, rather than leucocyte or 
P M N L  count, may therefore be considered as 
a measure of the degree of activation and local 
turnover of P M N L .*5 O ur m ethod of 
processing the SF samples, with immediate 
chilling and rapid cell separation, does prevent 
activation or lysis of PM N L  in vitro, so the 
lactoferrin concentrations may be considered 
to be representative of those in vivo.
The effects of IL-1 (3, T N F a  and IL -8 
include activation of PM NL, but the relative 
contribution of these cytokines to this 
activation is not known. The highly significant 
correlation between IL-6 and lactoferrin 
concentrations suggests that concentrations of 
IL -6 in SF parallel the degree of local P M N L
activation and turnover, regardless of the 
factors inducing this activation.
The results from sequential SF samples from 
the same patient suggest that relative changes 
in IL-6  concentrations over time are accom­
panied by similar relative changes in IL-8 , 
T N F a  and lactoferrin/PMNL activation but, 
surprisingly, not in IL -lp . The reason for this 
difference with IL -1 (3 is not clear from this 
study, as IL -1 is thought to be one of the major 
inducers of both IL -6  and IL-8 , The 
concentration of IL-1 in SF reflects both local 
production and local consumption of IL-1; the 
biological availability of IL -1 depends on the 
simultaneous production of IL-1 
antagonist (IL-1 RA )1,‘ and the change in 
balance between IL-1 and IL-1 RA over time. 
The same may be true for T N F a  and soluble 
TN F-receptors ,1* 17 However, it is not clear if 
the inhibitors of IL-1 and T N F a  have a 
comparable biological role.
It can be concluded from the present results 
that IL -6  in SF of RA patients may be 
considered as an indicator for local 
proinflammatory and potentially erosive 
activity of proinflammatory cytokines, and 
P M N L  activation. This supports the earlier 
findings that serum concentrations of acute 
phase proteins such as CRP, which are induced 
by IL-6 , are related to the progression of 
radiologically demonstrable joint damage .11
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